Verastem, Inc. (VSTM)
NASDAQ: VSTM · IEX Real-Time Price · USD
10.36
+0.38 (3.81%)
At close: May 2, 2024, 4:00 PM
10.11
-0.25 (-2.41%)
Pre-market: May 3, 2024, 8:00 AM EDT
Verastem Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
73
Market Cap
262.06M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
Dec 31, 2019 | 17.46M | -9.26M | -34.67% |
Dec 31, 2018 | 26.72M | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bioventus | 512.35M |
Sharecare | 445.25M |
23andMe Holding Co. | 247.99M |
Puma Biotechnology | 235.64M |
Agenus | 156.31M |
Senseonics Holdings | 22.39M |
Fennec Pharmaceuticals | 21.25M |
AC Immune | 17.62M |
VSTM News
- 14 days ago - Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer - Business Wire
- 4 weeks ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer - Business Wire
- 7 weeks ago - Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates - Business Wire
- 7 weeks ago - Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs - Business Wire
- 2 months ago - Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer - Business Wire
- 2 months ago - Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 - Business Wire
- 3 months ago - Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers - Business Wire